Skip to Content

Tilray Brands Inc TLRY Stock Quote

| Rating as of

Morningstar‘s Stock Analysis TLRY

Currency in CAD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Tilray Close to Positive Free Cash Flow in Fiscal 2023; Continued Slumping Shares Very Undervalued

Analyst Note

| Kristoffer Inton |

Tilray reported a decent fourth quarter and end to fiscal 2022, highlighted by its 13th straight quarter of positive adjusted EBITDA—a notable achievement as some Canada peers are years from breakeven. Gross cannabis revenue was up 23% from the third quarter, highlighted by an end to its Canada market struggles. Both Canada medical and adult-use sales grew sequentially, a relieving turnaround from the prior quarters’ declines. We continue to believe that more revenue growth and margin expansion is ahead but think it will take longer than we previously thought. As a result, we’ve cut our fair value estimates to $12 and CAD 15 per share, down from $14 and CAD 18, respectively for no-moat Tilray.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics TLRY

Company Profile TLRY

Business Description

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products through Manitoba Harvest and beer through SweetWater.

265 Talbot Street West
Leamington, ON, N8H 5L4, Canada
T +1 844 845-7291
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings May 31, 2022
Fiscal Year End May 31, 2023
Stock Type Speculative Growth
Employees 1,800